MiniMed™ 780G System Apple Watch

MiniMed™ 780G system

More Time in Range1, , day and night.

The MiniMed™ 780G system automatically  adjusts insulin delivery and corrects glucose levels every 5 minutes 24/7, requiring no finger pricks. 

Insulin pump user

Considering an automated insulin pump system?

When choosing an insulin pump, make sure it meets your needs and delivers the best results. Key considerations should include:

  • Time in Range (TIR):
    The percentage of time your blood glucose levels are within the target range. Higher TIR reduces complications like eye damage (retinopathy), heart and kidney disease2.
  • Burden reduction:
    Achieve more while doing less.  Your pump should help you to stay in range even when carb counting isn't exact3.

 

Things you should know about the MiniMed™ 780G

Advanced algorithm

The algorithm adapts to you providing better time in range than other systems.4

Wear what you want

Feel free to hide or show the pump 
depending on your outfit choice.

No daily charging

Unlike other pumps, the 780G doesn't need daily charging.

Freedom to disconnect 

Disconnect for up to an hour for activities.

Waterproof design 

A tough, easy-to-use pump.

Trusted across Europe

Used by hundreds of thousands, 780G is Europe’s most popular automated insulin pump.5

MiniMed™ 780G system

I can just eat, maybe make a wrong calculation but it will fix it by itself. 

Yonatan

MiniMed™ 780G user

Learn more about
the MiniMed™ 780G System.

Learn more

References

  1. Choudhary P, et al. Diabetes Technol Ther 2024; 26 (Suppl. 3): S32-S37.
  2. De Meulemeester J. The association of chronic complications with time in tight range and time in range in people with type 1 diabetes: a retrospective cross-sectional real-world study. Diabetologia. 2024;67(8):1527-1535. doi:10.1007/s00125-024-06171-y
  3. Petrovski G, et al. Diabetes Care 2023;46(3):544–550
  4. Di Molfetta S, Di Gioia L, Caruso I, et al. Efficacy and Safety of Different Hybrid Closed Loop Systems for Automated Insulin Delivery in People With Type 1 Diabetes: A Systematic Review and Network Meta-Analysis. Diabetes Metab Res Rev. 2024;40(6):e3842. doi:10.1002/dmrr.3842
  5. dQ&A Diabetes Technology Report, 2024 (n= 2,721)
  6. Fusselman H, et al. FUSS2015D-P - The Extended Wear Infusion Set - A Design for Plastic Waste Reduction. Virtual Diabetes Technology Meeting. 2020
  • * Compared to MDI + isCGM
  • ** Refer to System User Guide - SmartGuard™ feature. Some user interaction required
  • ^ A blood glucose (BG) reading is needed when entering SmartGuard™ feature. If glucose alerts and CGM readings do not match your symptoms, use a BG meter to make diabetes treatment decisions. Refer to System User Guide - SmartGuard™ feature. Some user interaction required.
  • ^^ Multiple Daily Injections (3 bolus and 1 basal insulin per day) requires 28 injections per week vs. 1 with Medtronic Extended Infusion Set.
  • # Arrieta A, et al. Diabetes Obes Metab. 2022;24(7):1370-1379. Mean 80% TIR is reached using the recommended optimal settings of 2 hours active insulin time and 100 mg/dL (5.5 mmol/L)as glucose target for at least 90% of the time.
  • ~ The patients testimonials relates an account of an individual´s response to the treatment. The account is genuine, typical and documented. However, the individual´s response does not provide any indication, guide, warranty or guarantee as to the response other patients may have to the treatment. The response other patients have to the treatment could be different. Responses to the treatment discussed can and do vary and specific to the individual patient.
  • ¥ Refer to Accu-Chek® Guide Link User's Manual
    • 1.Choudhary P, et al. Diabetes Technol Ther 2024; 26 (Suppl. 3): S32-S37.
    • 2.De Meulemeester J. The association of chronic complications with time in tight range and time in range in people with type 1 diabetes: a retrospective cross-sectional real-world study. Diabetologia. 2024;67(8):1527-1535. doi:10.1007/s00125-024-06171-y
    • 3.Petrovski G, et al. Diabetes Care 2023;46(3):544–550
    • 4.Di Molfetta S, Di Gioia L, Caruso I, et al. Efficacy and Safety of Different Hybrid Closed Loop Systems for Automated Insulin Delivery in People With Type 1 Diabetes: A Systematic Review and Network Meta-Analysis. Diabetes Metab Res Rev. 2024;40(6):e3842. doi:10.1002/dmrr.3842
    • 5.dQ&A Diabetes Technology Report, 2024 (n= 2,721)
    • 6.Fusselman H, et al. FUSS2015D-P - The Extended Wear Infusion Set - A Design for Plastic Waste Reduction. Virtual Diabetes Technology Meeting. 2020
    • 1.Choudhary P, et al. Diabetes Technol Ther 2024; 26 (Suppl. 3): S32-S37.
    • 2.De Meulemeester J. The association of chronic complications with time in tight range and time in range in people with type 1 diabetes: a retrospective cross-sectional real-world study. Diabetologia. 2024;67(8):1527-1535. doi:10.1007/s00125-024-06171-y
    • 3.Petrovski G, et al. Diabetes Care 2023;46(3):544–550
    • * Compared to MDI + isCGM
    • ** Refer to System User Guide - SmartGuard™ feature. Some user interaction required
    • ^ A blood glucose (BG) reading is needed when entering SmartGuard™ feature. If glucose alerts and CGM readings do not match your symptoms, use a BG meter to make diabetes treatment decisions. Refer to System User Guide - SmartGuard™ feature. Some user interaction required.
    • ^^ Multiple Daily Injections (3 bolus and 1 basal insulin per day) requires 28 injections per week vs. 1 with Medtronic Extended Infusion Set.
    • # Arrieta A, et al. Diabetes Obes Metab. 2022;24(7):1370-1379. Mean 80% TIR is reached using the recommended optimal settings of 2 hours active insulin time and 100 mg/dL (5.5 mmol/L)as glucose target for at least 90% of the time.
    • ~ The patients testimonials relates an account of an individual's response to the treatment. The account is genuine, typical and documented. However, the individual's response does not provide any indication, guide, warranty or guarantee as to the response other patients may have to the treatment. The response other patients have to the treatment could be different. Responses to the treatment discussed can and do vary and specific to the individual patient.
    • ¥ Refer to Accu-Chek® Guide Link User's Manual
    • ** Refer to System User Guide - SmartGuard™ feature. Some user interaction required
    • ^ A blood glucose (BG) reading is needed when entering SmartGuard™ feature. If glucose alerts and CGM readings do not match your symptoms, use a BG meter to make diabetes treatment decisions. Refer to System User Guide - SmartGuard™ feature. Some user interaction required.

    All clinical data and surveys results included in this document refer to MiniMed™ 780G system used in combination with Guardian™ sensor 3. Information contained herein is not medical advice and should not be used as an alternative to speaking with your doctor. Discuss indications, contraindications, warnings, precautions, potential adverse events and any further information with your health care professional.

    UK-IPT-2300128©2023 Medtronic. All rights reserved Medtronic. Medtronic logo and Further, Together are trademarks of Medtronic. Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company. ACCU-CHEK AND ACCU-CHEK GUIDE LINK are trademarks of Roche Diabetes Care. DreaMed Diabetes is a trademark of DreaMed Diabetes. Ltd. The MiniMed™ 780G system algorithm includes technology developed by DreaMed Diabetes. The legal manufacturer of MiniMed™ Mio ™ Advance infusion set is Unomedical a/s. Aaholmvej 1-3, Osted. 4320 Lejre, Denmark.